Bucheon, South Korea · Founded 2017 · Privately Held (backing)
Operator of a biomedical company intended to make botulinum toxin. Inibio is based in Bucheon, South Korea and was founded in 2017. Its last reported valuation was $129 million in Feb 2025.
Last reported valuation
$129.2M
Oct 2026
Priced at
—
Total raised
—
Last round
—
Cap table — not yet on record
Inibio's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Inibio with a free account
·Watch Inibio: the Monday email on marks, rounds and moves
